# A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

> **NCT04426968** · PHASE2 · COMPLETED · sponsor: **Shanghai HEP Pharmaceutical Co., Ltd.** · enrollment: 96 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Hepalatide 2.1mg
- **DRUG:** Hepalatide 4.2mg
- **DRUG:** Hepalatide 6.3mg
- **DRUG:** placebo 2.1mg
- **DRUG:** placebo 4.2mg
- **DRUG:** placebo 6.3mg
- **DRUG:** Pegylated Interferon

## Key facts

- **NCT ID:** NCT04426968
- **Lead sponsor:** Shanghai HEP Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-18
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-11-29
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04426968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04426968, "A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04426968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*